Hello, everyone, and welcome to the middle of the week, which arrived rather quickly, yes? This is a good sign, since it means the week is barreling along as you continue your struggle after the holiday break to get in sync with the usual daily routines. So have heart, the weekend is not that far off. This is the encouragement we offered our shortest person as the schoolhouse bus arrived. Easier said than done, though. In any event, time to get cracking. So here are a few items of interest to push you forward. Hope your day is splendid and, of course, do keep in touch …
The U.K.’s National Institute for Health and Care Excellence issued final draft guidance approving the GlaxoSmithKline (GSK) gene therapy, Strimvelis, for an ultra-rare immune deficiency condition known as bubble boy syndrome. At nearly $717,000, the list price for the one-time treatment makes Strimvelis the most expensive medicine ever recommended in the U.K., Bloomberg News notes.
Three children recently immunized with Dengvaxia, the Sanofi (SNY) dengue vaccine, are now hospitalized with possible dengue infections, Cidrap writes, citing The Manila Times. The hospitalizations come one month after Sanofi recommended Dengvaxia not be used in anyone who has not had dengue, because it can cause more severe illness in those not previously infected. And a new study shows Dengvaxia may affect the accuracy of dengue diagnostic tests.
About the Author Reprints
